

the accomplishment of the various identified objectives of the cooperative agreement. Measures of effectiveness must relate to the performance goals stated in the "Purpose" section of this announcement. Measures must be objective and quantitative, and must measure the intended outcome. These measures of effectiveness must be submitted with the application and will be an element of evaluation. These should be included in your project narrative under "4. Goals."

Your application will be evaluated against the following criteria:

A. Current Capability: 80 Total

1. Clinical Care: 20

Does the applicant demonstrate significant experience in implementing or assisting HIV care and treatment programs in the proposed countries? Does the applicant describe technically sound clinical care protocols? Is the applicant currently providing ART?

2. Drug & Health Commodities: 15

Does the applicant describe all aspects of drug management? Do procedures appear to be adequate, including to prevent theft and diversion?

3. Laboratory Services: 15

Are facilities adequate? Are staff qualified? Are there adequate quality assurance measures in place? Is the lab capable of performing a broad range of tests? Can the lab perform CD4 tests?

4. Training: 10

Does the applicant have a history of providing training on a broad number of relevant topics to all levels of staff?

5. Community Mobilization and Behavior: 5

Does the applicant describe efforts to promote testing and plans to provide counseling? Did the applicant describe methods to increase the number of persons who seek HIV testing and methods to increase the number of persons to whom it will provide counseling? Did the applicant describe efforts to support adherence to therapy?

6. Monitoring and Evaluation: 10

Is there a M&E plan in place? Does the plan measure indicators that track program performance?

7. Sustainability: 5

Is the plan for sustainability reasonable and feasible?

B. Feasibility of Expansion Plan: 80 Total

1. Clinical care: 25

Does the applicant propose to provide ART in three or more of the eligible countries? Is the plan to increase the number of persons receiving ART feasible? Is the estimated cost per patient reasonable? Are plans to assure quality of care adequate? Does the applicant demonstrate consistency with national plans?

2. Drug & Health Commodities: 15

Are plans to provide services and assure quality adequate?

3. Laboratory Services: 15

Is the plan to increase laboratory services feasible?

4. Training: 15

Is the plan to expand training feasible? Does the training plan address the needs of the program? Does the applicant address training needs of indigenous staff?

5. Community Mobilization and Behavior: 5

Did the applicant describe how the program will increase the number of persons tested and counseled?

6. Monitoring and Evaluation: 5

Does the plan measure indicators that track program performance?

C. Organizational Structure, Management, and Staffing: 20 Total

1. Organizational Structure: 7

Is the proposed mix of organizations adequate to achieve program objectives? Were letters of support including those of the MOH provided?

2. Staffing: 8

Are the number and types of staff reasonable? Does the applicant provide a realistic sustainability plan?

3. Facilities: 5

Are the facilities adequate to provide the proposed services?

D. Measures of effectiveness: 10 Total

Do the measures of effectiveness address the number of persons receiving ART and clinical outcomes? Are timelines reasonable?

E. Budget: 10 Points

Is the budget reasonable for the proposed activities?

V.2. Review and Selection Process

Applications will be reviewed for completeness by the Procurement and Grants Office (PGO) staff, and for

responsiveness. Incomplete applications and applications that are non-responsive to the eligibility criteria will not advance through the review process. Applicants will be notified that their application did not meet submission requirements.

An objective review panel will evaluate complete and responsive applications according to the criteria listed in the "V.1. Criteria" section above.

In addition, the following factors may affect the funding decision:

- Geographic distribution—to ensure that funding is not concentrated in any one catchment area.
- Cost sharing.
- Number of persons to be treated.
- No award will be made without the concurrence of the U.S. Embassy and the CDC representative in the country under consideration.

V.3. Anticipated Announcement Award Date

January 15, 2004.

VI. Award Administration Information

VI.1. Award Notices

Successful applicants will receive a Notice of Grant Award (NGA) from the CDC Procurement and Grants Office. The NGA shall be the only binding, authorizing document between the recipient and CDC. The NGA will be signed by an authorized Grants Management Officer, and mailed to the recipient fiscal officer identified in the application.

Unsuccessful applications will receive notification of the results of the application review by mail.

VI.2. Administrative and National Policy Requirements

45 CFR Part 74 and Part 92.

For more information on the Code of Federal Regulations, see the National Archives and Records Administration at the following Internet address: <http://www.access.gpo.gov/nara/cfr/cfr-table-search.html>

The following additional requirements apply to this project:

- AR-1 Human Subjects Requirements
- AR-4 HIV/AIDS Confidentiality Provisions
- AR-5 HIV Program Review Panel Requirements
- AR-6 Patient Care
- AR-9 Paperwork Reduction Act Requirements
- AR-10 Smoke-Free Workplace Requirements
- AR-12 Lobbying Restrictions
- AR-14 Accounting System Requirements